MA35924B1 - Dosages biologiques de contrôle qualité à base de cellules pour des produits nutraceutiques et médicinaux - Google Patents
Dosages biologiques de contrôle qualité à base de cellules pour des produits nutraceutiques et médicinauxInfo
- Publication number
- MA35924B1 MA35924B1 MA37323A MA37323A MA35924B1 MA 35924 B1 MA35924 B1 MA 35924B1 MA 37323 A MA37323 A MA 37323A MA 37323 A MA37323 A MA 37323A MA 35924 B1 MA35924 B1 MA 35924B1
- Authority
- MA
- Morocco
- Prior art keywords
- cell
- level
- nutraceutical
- quality control
- proliferation inhibition
- Prior art date
Links
- 238000004166 bioassay Methods 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000002417 nutraceutical Substances 0.000 title 1
- 235000021436 nutraceutical agent Nutrition 0.000 title 1
- 238000003908 quality control method Methods 0.000 title 1
- 230000035755 proliferation Effects 0.000 abstract 5
- 230000005764 inhibitory process Effects 0.000 abstract 4
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 230000014621 translational initiation Effects 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/02—Food
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261674180P | 2012-07-20 | 2012-07-20 | |
| PCT/US2013/051433 WO2014015328A1 (en) | 2012-07-20 | 2013-07-22 | Cell based quality control bioassays for nutriceutical and medicinal products |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35924B1 true MA35924B1 (fr) | 2014-12-01 |
Family
ID=48916225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37323A MA35924B1 (fr) | 2012-07-20 | 2014-09-04 | Dosages biologiques de contrôle qualité à base de cellules pour des produits nutraceutiques et médicinaux |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9952200B2 (enExample) |
| EP (1) | EP2820418B1 (enExample) |
| JP (1) | JP6200501B2 (enExample) |
| KR (1) | KR102136763B1 (enExample) |
| CN (1) | CN104641231B (enExample) |
| AU (1) | AU2013292266B2 (enExample) |
| CA (1) | CA2866175C (enExample) |
| CL (1) | CL2014002530A1 (enExample) |
| CO (1) | CO7151536A2 (enExample) |
| DK (1) | DK2820418T3 (enExample) |
| ES (1) | ES2656941T3 (enExample) |
| HU (1) | HUE036166T2 (enExample) |
| IN (1) | IN2014DN07866A (enExample) |
| MA (1) | MA35924B1 (enExample) |
| MX (1) | MX356147B (enExample) |
| NO (1) | NO2912013T3 (enExample) |
| PE (1) | PE20142297A1 (enExample) |
| PL (1) | PL2820418T3 (enExample) |
| PT (1) | PT2820418T (enExample) |
| RU (1) | RU2662358C2 (enExample) |
| WO (1) | WO2014015328A1 (enExample) |
| ZA (1) | ZA201406653B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107217087B (zh) * | 2016-03-22 | 2019-12-10 | 中国石油化工股份有限公司 | 迅速测量油田污水和成品油中细菌含量的方法 |
| CN115785247B (zh) * | 2022-12-22 | 2025-06-24 | 中国农业大学 | 一种猪流行性腹泻病毒抗性相关蛋白质eif2a及其相关生物材料和应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4318846A (en) | 1979-09-07 | 1982-03-09 | Syva Company | Novel ether substituted fluorescein polyamino acid compounds as fluorescers and quenchers |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4757141A (en) | 1985-08-26 | 1988-07-12 | Applied Biosystems, Incorporated | Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof |
| US5091519A (en) | 1986-05-01 | 1992-02-25 | Amoco Corporation | Nucleotide compositions with linking groups |
| US5151507A (en) | 1986-07-02 | 1992-09-29 | E. I. Du Pont De Nemours And Company | Alkynylamino-nucleotides |
| US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| US5066580A (en) | 1988-08-31 | 1991-11-19 | Becton Dickinson And Company | Xanthene dyes that emit to the red of fluorescein |
| US5366860A (en) | 1989-09-29 | 1994-11-22 | Applied Biosystems, Inc. | Spectrally resolvable rhodamine dyes for nucleic acid sequence determination |
| US5188934A (en) | 1989-11-14 | 1993-02-23 | Applied Biosystems, Inc. | 4,7-dichlorofluorescein dyes as molecular probes |
| US5654419A (en) | 1994-02-01 | 1997-08-05 | The Regents Of The University Of California | Fluorescent labels and their use in separations |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| US5800996A (en) | 1996-05-03 | 1998-09-01 | The Perkin Elmer Corporation | Energy transfer dyes with enchanced fluorescence |
| US5847162A (en) | 1996-06-27 | 1998-12-08 | The Perkin Elmer Corporation | 4, 7-Dichlororhodamine dyes |
| US6322901B1 (en) | 1997-11-13 | 2001-11-27 | Massachusetts Institute Of Technology | Highly luminescent color-selective nano-crystalline materials |
| US5990479A (en) | 1997-11-25 | 1999-11-23 | Regents Of The University Of California | Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes |
| US6207392B1 (en) | 1997-11-25 | 2001-03-27 | The Regents Of The University Of California | Semiconductor nanocrystal probes for biological applications and process for making and using such probes |
| US6426513B1 (en) | 1998-09-18 | 2002-07-30 | Massachusetts Institute Of Technology | Water-soluble thiol-capped nanocrystals |
| US6251303B1 (en) | 1998-09-18 | 2001-06-26 | Massachusetts Institute Of Technology | Water-soluble fluorescent nanocrystals |
| US6649138B2 (en) | 2000-10-13 | 2003-11-18 | Quantum Dot Corporation | Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media |
| US6576291B2 (en) | 2000-12-08 | 2003-06-10 | Massachusetts Institute Of Technology | Preparation of nanocrystallites |
| ATE556845T1 (de) | 2001-07-20 | 2012-05-15 | Life Technologies Corp | Lumineszierende nanopartikel und ihre herstellung |
| WO2007008221A2 (en) * | 2004-08-10 | 2007-01-18 | President And Fellows Of Harvard College | DETECTION OF PHOSPHORYLATED eIF2α AS A DIAGNOSTIC TEST FOR EFFICIENCY AND SENSITVITY OF TRANSLATION INITIATION INHIBITORS IN THE TREATMENT OF CANCER AND OTHE R PROLIFERATIVE DISEASES |
| WO2008008333A2 (en) * | 2006-07-11 | 2008-01-17 | President And Fellows Of Harvard College | Bioassays for quality control of nutriceuticals that inhibit, upregulate or otherwise modulate translation initiation |
| JP2012523837A (ja) * | 2009-04-17 | 2012-10-11 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 栄養医薬品および医薬品のための品質管理バイオアッセイ |
| CA2763589A1 (en) * | 2009-05-28 | 2010-12-02 | President And Fellows Of Harvard College | N,n'-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation |
| CN101671669B (zh) * | 2009-08-27 | 2012-05-02 | 浙江大学 | 一种肝癌靶向性基因表达元件ae及其应用 |
-
2013
- 2013-07-22 IN IN7866DEN2014 patent/IN2014DN07866A/en unknown
- 2013-07-22 MX MX2014012542A patent/MX356147B/es active IP Right Grant
- 2013-07-22 DK DK13745268.6T patent/DK2820418T3/en active
- 2013-07-22 CN CN201380031597.XA patent/CN104641231B/zh not_active Expired - Fee Related
- 2013-07-22 US US14/382,116 patent/US9952200B2/en active Active
- 2013-07-22 PE PE2014001438A patent/PE20142297A1/es active IP Right Grant
- 2013-07-22 EP EP13745268.6A patent/EP2820418B1/en active Active
- 2013-07-22 JP JP2015523300A patent/JP6200501B2/ja not_active Expired - Fee Related
- 2013-07-22 RU RU2014136408A patent/RU2662358C2/ru active
- 2013-07-22 PL PL13745268T patent/PL2820418T3/pl unknown
- 2013-07-22 WO PCT/US2013/051433 patent/WO2014015328A1/en not_active Ceased
- 2013-07-22 AU AU2013292266A patent/AU2013292266B2/en not_active Ceased
- 2013-07-22 KR KR1020147026323A patent/KR102136763B1/ko not_active Expired - Fee Related
- 2013-07-22 ES ES13745268.6T patent/ES2656941T3/es active Active
- 2013-07-22 HU HUE13745268A patent/HUE036166T2/hu unknown
- 2013-07-22 PT PT137452686T patent/PT2820418T/pt unknown
- 2013-07-22 CA CA2866175A patent/CA2866175C/en active Active
- 2013-10-25 NO NO13849263A patent/NO2912013T3/no unknown
-
2014
- 2014-09-04 MA MA37323A patent/MA35924B1/fr unknown
- 2014-09-10 ZA ZA2014/06653A patent/ZA201406653B/en unknown
- 2014-09-19 CO CO14208659A patent/CO7151536A2/es unknown
- 2014-09-24 CL CL2014002530A patent/CL2014002530A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2014002530A1 (es) | 2015-01-09 |
| KR20150035496A (ko) | 2015-04-06 |
| EP2820418A1 (en) | 2015-01-07 |
| JP6200501B2 (ja) | 2017-09-20 |
| ES2656941T3 (es) | 2018-03-01 |
| MX2014012542A (es) | 2014-11-21 |
| US20150301023A1 (en) | 2015-10-22 |
| NO2912013T3 (enExample) | 2018-03-10 |
| AU2013292266B2 (en) | 2019-01-03 |
| KR102136763B1 (ko) | 2020-08-13 |
| US9952200B2 (en) | 2018-04-24 |
| CA2866175A1 (en) | 2014-01-23 |
| RU2662358C2 (ru) | 2018-07-25 |
| CA2866175C (en) | 2021-04-20 |
| PE20142297A1 (es) | 2014-12-19 |
| PL2820418T3 (pl) | 2018-05-30 |
| EP2820418B1 (en) | 2017-12-06 |
| JP2015524269A (ja) | 2015-08-24 |
| ZA201406653B (en) | 2022-05-25 |
| AU2013292266A1 (en) | 2014-09-25 |
| RU2014136408A (ru) | 2016-09-10 |
| CN104641231B (zh) | 2016-09-07 |
| DK2820418T3 (en) | 2018-02-12 |
| CN104641231A (zh) | 2015-05-20 |
| IN2014DN07866A (enExample) | 2015-04-24 |
| MX356147B (es) | 2018-05-15 |
| PT2820418T (pt) | 2018-02-12 |
| CO7151536A2 (es) | 2014-12-29 |
| HUE036166T2 (hu) | 2018-06-28 |
| WO2014015328A1 (en) | 2014-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ando et al. | A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes | |
| Rousseau et al. | An evolutionarily conserved pathway controls proteasome homeostasis | |
| Pons et al. | Mortality and cause of death in patients with heart failure: findings at a specialist multidisciplinary heart failure unit | |
| EA201991105A1 (ru) | Методы оценки риска с использованием общей и специфической неклеточной днк | |
| Liang et al. | Rad23 interaction with the proteasome is regulated by phosphorylation of its ubiquitin-like (UbL) domain | |
| Kimball et al. | Induction of REDD1 gene expression in the liver in response to endoplasmic reticulum stress is mediated through a PERK, eIF2α phosphorylation, ATF4-dependent cascade | |
| EA202090517A1 (ru) | Способы определения донорской внеклеточной днк без генотипа донора | |
| BR112018002428A2 (pt) | “anticorpos, polinucleotídeo, vetor, célula, método de expressar o anticorpo, kit, método para detectar a presença ou o nível de pd-l1 humano ou de macaco em uma amostra, método de identificação de um indivíduo com um distúrbio, método para monitorar a resposta terapêutica, composição farmacêutica,método para tratar uma condição em um sujeito e uso do anticorpo | |
| EA202092319A1 (ru) | Способы получения опухоль-инфильтрирующих лимфоцитов и применения их в иммунотерапии | |
| FR3034523B1 (fr) | Nouvelle methode pour detecter la presence de bacteries productrices de beta-lactamases. | |
| WO2020087037A3 (en) | Disease stratification of liver disease and related methods | |
| MX2012003997A (es) | Biomarcadores para predecir la sensibilidad y respuesta de enfermedades mediadas por proteina cinasa ck2 a inhibidores de ck2. | |
| ATE471512T1 (de) | Verwendung des proteins s100a 12 als marker für kolorektalkarzinom | |
| BR112022011676A2 (pt) | Kit para detectar um analito de interesse em uma pluralidade de amostras líquidas biológicas, método para detectá-lo e /ou quantificá-lo e cartucho para realizar tal método | |
| ES2863274T3 (es) | Biomarcador de muerte celular | |
| EP4513499A3 (en) | Method and device for analyzing target analyte in sample | |
| MA35924B1 (fr) | Dosages biologiques de contrôle qualité à base de cellules pour des produits nutraceutiques et médicinaux | |
| Molon et al. | The longevity in the yeast Saccharomyces cerevisiae: A comparison of two approaches for assessment the lifespan | |
| Marquez-Lona et al. | Phosphorylation of the 19S regulatory particle ATPase subunit, Rpt6, modifies susceptibility to proteotoxic stress and protein aggregation | |
| ATE468535T1 (de) | Verwendung von nnmt als marker für lungenkrebs | |
| MX2019012169A (es) | Ensayos para evaluar la actividad de moduladores de miembros de la familia de hidroxiesteroide (17-beta) deshidrogenasa (hsd17b). | |
| EP4211259A4 (en) | ELECTROCHEMICAL BIOSENSOR FOR DETECTION OF TARGET ANALYTE | |
| Dikovskaya et al. | Measuring the interaction of transcription factor Nrf2 with its negative regulator Keap1 in single live cells by an improved FRET/FLIM analysis | |
| MX2020008348A (es) | Prediccion de perdida de embarazo. | |
| MX378728B (es) | Ensayo de inflamacion oral. |